{"name":"Guangzhou Gloria Biosciences Co., Ltd.","slug":"guangzhou-gloria-biosciences-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Chemotherapy of Investigator's choice","genericName":"Chemotherapy of Investigator's choice","slug":"chemotherapy-of-investigator-s-choice","indication":"Cancer (specific type and stage determined by investigator selection)","status":"phase_3"},{"name":"Motixafortide+G-CSF","genericName":"Motixafortide+G-CSF","slug":"motixafortide-g-csf","indication":"Hematopoietic stem cell mobilization in patients with multiple myeloma or lymphoma undergoing autologous stem cell transplantation","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GLS-010","genericName":"GLS-010","slug":"gls-010","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Placebo+G-CSF","genericName":"Placebo+G-CSF","slug":"placebo-g-csf","indication":"Neutropenia","status":"phase_3"}]}],"pipeline":[{"name":"GLS-010","genericName":"GLS-010","slug":"gls-010","phase":"phase_3","mechanism":"GLS-010 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Chemotherapy of Investigator's choice","genericName":"Chemotherapy of Investigator's choice","slug":"chemotherapy-of-investigator-s-choice","phase":"phase_3","mechanism":"This is a phase 3 chemotherapy regimen selected by the investigator to treat cancer, with the specific mechanism dependent on the chosen chemotherapeutic agent(s).","indications":["Cancer (specific type and stage determined by investigator selection)"],"catalyst":""},{"name":"Motixafortide+G-CSF","genericName":"Motixafortide+G-CSF","slug":"motixafortide-g-csf","phase":"phase_3","mechanism":"Motixafortide is a CXCR4 antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood, used in combination with G-CSF (granulocyte-colony stimulating factor) to enhance stem cell mobilization for transplantation.","indications":["Hematopoietic stem cell mobilization in patients with multiple myeloma or lymphoma undergoing autologous stem cell transplantation"],"catalyst":""},{"name":"Placebo+G-CSF","genericName":"Placebo+G-CSF","slug":"placebo-g-csf","phase":"phase_3","mechanism":"G-CSF stimulates the bone marrow to produce more neutrophils, a type of white blood cell.","indications":["Neutropenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPVkxNdDJJWHdEbjRZeTJyYmU1blJDR2NMcWQySGRXbzd3dXhybWZJT3pRcUtGOU0zMmFadG9zY0NHS21ZT0dJUTZ5WEowa1VjMlhhZmdOT0N5TXhKS0M0cndvcUtOUTY2eG5wc1Z1SVFQVUI4Z3Q0RVpZMGV1VXpkelVhS0h4dlJXd24wZlRZZk1DV1UyRi1DWGd2SXNOUTN3UVZ1OUtlS3FaUkdRLUhWTDNkOGJOUWxxbjM0Zw?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"BioLineRx (NASDAQ: BLRX) files Form 20-F/A to correct auditor consent - Stock Titan","headline":"BioLineRx (NASDAQ: BLRX) files Form 20-F/A to correct auditor consent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5OZkxKaVcxWGx5akN1LV9sbGduOEFFdUtaMDJuMjFfUEtmSmllTkw3R2lHc0tnV1ZNMVFrWjc0MWVxT2N2OU9YclBUOVVRa1dUanFn?oc=5","date":"2025-10-13","type":"trial","source":"FirstWord Pharma","summary":"Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - FirstWord Pharma","headline":"Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPbS12N3Q2VjFXVVBJNUREOVE0NE9FLWhkbG5Jcnk2WEtJVk9oRHNhRk9OWXJxb2tQYjJDSnEtRHFWcVBQMzRwU2JYS05kR1FCM0pEbE1kZnpjZWNoaU1xZGt1VXE0Z0I4UkgtSnVTMjdRdEpFWHp5WDlUQ2ZBNXY1OWVHelp0R3JJLV9VdXJBQmRNRHRia2NzeXFITWJWcFhZdjMtSzY3ZkZhLUVONDFNUE54bHFCT0dnRFBNdFdYbG40M1hMLW51WTlLQTNNRExUMjVHa0VqUjBuRll3UkdVRUlmaHg2Q2RDUWxQNnhjZFZXLU5JVUVUa3c3eWxZX2JyVGp3RE84dw?oc=5","date":"2023-09-06","type":"regulatory","source":"prnewswire.com","summary":"Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer - prnewswire.com","headline":"Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer","sentiment":"positive"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}